CD274 and non-small cell lung carcinoma: As a first-line therapy, the phase III KEYNOTE 024 trial explored the use of pembrolizumab in advanced NSCLC with at least 50% PD-L1 staining versus cytotoxic chemotherapy, which was up to the discretion of the treating physician.